Journal Article Summary
The article investigates how oral and transdermal hormonal contraceptives interact with protease inhibitors, specifically lopinavir/ritonavir (LPV/r), in women infected with HIV-1. This topic is significant because effective contraception is crucial for HIV-infected women, who often wish to delay childbearing until their health is stable. Understanding these interactions can help healthcare providers make informed decisions about contraceptive options for women undergoing antiretroviral therapy, ensuring both effective family planning and the prevention of mother-to-child transmission of HIV.
The study involved 32 nonpregnant, premenopausal HIV-1-infected women, with 8 on LPV/r and 24 in a control group not receiving antiretroviral therapy. Researchers measured the pharmacokinetics (PK) of ethinyl estradiol (EE) and norelgestromin (NGMN) from a transdermal contraceptive patch and a single oral contraceptive pill. The findings revealed that the median EE levels were significantly lower in women taking LPV/r compared to the control group, while NGMN levels were higher. Despite these changes, the study suggests that the contraceptive efficacy of the patch is likely maintained, although further research is needed to confirm these results.
Limitations of the study include its premature closure due to slow participant recruitment and a small sample size, which may affect the reliability of the findings. Additionally, while the study indicates that contraceptive efficacy is likely preserved, it does not provide definitive conclusions about the safety and risks associated with hormonal contraception in this population. Patients should discuss their contraceptive options and any concerns about drug interactions with their healthcare providers, especially if they are on antiretroviral therapy, to ensure safe and effective family planning.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Vogler Mary A., Patterson Kristine, Kamemoto Lori, Park Jeong-Gun, Watts Heather, Aweeka Francesca, Klingman Karin L., Cohn Susan E.. Contraceptive Efficacy of Oral and Transdermal Hormones When Co-Administered With Protease Inhibitors in HIV-1–Infected Women: Pharmacokinetic Results of ACTG Trial A5188. Journal of acquired immune deficiency syndromes (1999) 2010. DOI: 10.1097/QAI.0b013e3181eb5ff5. PMID: 20842042. PMCID: PMC4197050.
Featured Pill Pals Product
OPill (O-Pill) Norgestrel Tablets 0.075 mg Daily Oral Contraceptive --- Perrigo
OPill (O-Pill) Norgestrel Tablets 0.075 mg Daily Oral Contraceptive --- Perrigo is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. No prescription required for eligible over-the-counter purchases.
